Editas' share price has struggled due to clinical setbacks, but recent focus on in-vivo gene editing offers renewed hope and upside potential. The company is valued near cash levels, with $221M on ...

California's long-lost grizzly bear may be inching closer to a comeback. A bill moving through the state legislature would not bring the predator back immediately, but it would require officials to ...

Liverpool’s Pursuit of Alexander Isak: Ambitious or Unrealistic? Liverpool’s ambitions in the summer market are as bold as ever following a Premier League title in Arne Slot’s debut season. With deals ...